There is a version of the life sciences CEO that the industry tends to celebrate: visionary, decisive, comfortable with risk.
Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan ...
Novartis investors are placing increased pressure on Novartis’ dealmaking strategy after facing setbacks to drugs acquired ...
The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human ...
Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following ...
An oversubscribed $70 million Series B, co-led by Alpha Wave and YK Bioventures with Eli Lilly participation, funds clinical ...
The health care industry has invested heavily in point solutions ($100 billion). We have one tool for scheduling, another for ...
The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA ...
Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...
Ultragenyx is reviewing program disposition and implementing significant expense reductions as brokerages cut price targets ...
Our survey findings highlight the critical need for reforms to ensure that IBD patients can access the medications they need ...
FDA approved zilganersen as the first disease-modifying therapy for Alexander disease, an ultra-rare, progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results